The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.
The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.